Smithbridge Asset Management Inc. DE Has $3.47 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Smithbridge Asset Management Inc. DE reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.8% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,303 shares of the biopharmaceutical company’s stock after selling 572 shares during the period. Smithbridge Asset Management Inc. DE’s holdings in Regeneron Pharmaceuticals were worth $3,472,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. SVB Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 40.0% in the fourth quarter. SVB Wealth LLC now owns 1,117 shares of the biopharmaceutical company’s stock valued at $981,000 after buying an additional 319 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 3.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 15,086 shares of the biopharmaceutical company’s stock valued at $13,250,000 after acquiring an additional 514 shares during the period. Federated Hermes Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 14.9% in the 4th quarter. Federated Hermes Inc. now owns 3,214 shares of the biopharmaceutical company’s stock valued at $2,823,000 after purchasing an additional 418 shares during the period. Delta Financial Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 7.8% in the 4th quarter. Delta Financial Advisors LLC now owns 1,380 shares of the biopharmaceutical company’s stock valued at $1,212,000 after purchasing an additional 100 shares during the last quarter. Finally, AIA Group Ltd grew its holdings in Regeneron Pharmaceuticals by 13.6% during the fourth quarter. AIA Group Ltd now owns 4,722 shares of the biopharmaceutical company’s stock worth $4,147,000 after purchasing an additional 565 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 787 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the sale, the chief executive officer now owns 64,198 shares of the company’s stock, valued at approximately $65,162,253.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Leonard S. Schleifer sold 787 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now owns 64,198 shares of the company’s stock, valued at $65,162,253.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders sold a total of 17,731 shares of company stock valued at $18,230,142 in the last quarter. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $3.98 during trading on Friday, reaching $1,179.31. 564,438 shares of the company’s stock were exchanged, compared to its average volume of 483,981. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,185.09. The company has a market cap of $130.01 billion, a P/E ratio of 34.84, a PEG ratio of 3.06 and a beta of 0.13. The firm’s 50-day moving average price is $1,070.90 and its 200 day moving average price is $995.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the prior year, the business earned $8.79 earnings per share. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on REGN shares. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. Argus lifted their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,097.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.